WO2000009105A3 - Small molecule carbamates or ureas for vision and memory disorders - Google Patents

Small molecule carbamates or ureas for vision and memory disorders Download PDF

Info

Publication number
WO2000009105A3
WO2000009105A3 PCT/US1999/018237 US9918237W WO0009105A3 WO 2000009105 A3 WO2000009105 A3 WO 2000009105A3 US 9918237 W US9918237 W US 9918237W WO 0009105 A3 WO0009105 A3 WO 0009105A3
Authority
WO
WIPO (PCT)
Prior art keywords
vision
ureas
small molecule
memory disorders
international
Prior art date
Application number
PCT/US1999/018237
Other languages
French (fr)
Other versions
WO2000009105A2 (en
Inventor
Douglas T Ross
Hansjorg Sauer
Gregory S Hamilton
Joseph P Steiner
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Priority to CA002336060A priority Critical patent/CA2336060A1/en
Priority to EP99942106A priority patent/EP1105131A2/en
Priority to MXPA01000596A priority patent/MXPA01000596A/en
Priority to JP2000564608A priority patent/JP2002522481A/en
Priority to AU55554/99A priority patent/AU5555499A/en
Publication of WO2000009105A2 publication Critical patent/WO2000009105A2/en
Publication of WO2000009105A3 publication Critical patent/WO2000009105A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Abstract

This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance using small molecule carbamates and ureas.

Description

Figure imgf000003_0001
Figure imgf000004_0001
Form PCTV.SΛ 210 (contlnu-dα. of second sheet) (July 1β92) G(Contnuation) DOCUMENTS CONSIDERED TO BE RELEVANT
Category " Citation of document wtth tho-catioαwhere appropriate, of the relevant passages Relevant to d-Um No.
DATABASE CHEMABS 'Online! 1-4,
CHEMICAL ABSTRACTS SERVICE, COLUMBUS, 16-21
OHIO, US
BALASPIRI, LAJOS ET AL: "Producing new trlpeptide derivatives of anti-amnesic activity" retrieved from STN
Database accession no. 110:24315 HCA
Figure imgf000005_0001
d s'ps.c
& HU 43622 A (RICHTER, GEDEON, VEGYESZETI
GYAR RT., HUNG.)
30 November 1987 (1987-11-30)
PESSAH, I. H. (1): "Role for the major 1-21 T-cell immunophilin FKBP12 in mediating neurotoxicity of non-coplanar PCBs." NEUR0T0XIC0L0GY AND TERATOLOGY, (MAY-JUNE, 1998) VOL. 20, NO. 3, PP. 350. MEETING INFO.: TWENTY-SECOND ANNUAL MEETING OF THE NEUROBEHAVIORAL TERATOLOGY SOCIETY SAN DIEGO, CALIFORNIA, USA JUNE 20-24, 1998 NEUROBEHAVIORAL TERATOLOGY SOCIETY. , XP000878599 the whole document
Ram PCTΛSΛ210 (ocntlnualion of second sheet) (Jiiy 19-2) ..■temationaJ application No.
INTERNATIONAL SEARCH REPORT PCT/ US 99/ 18237
Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established In respect of certain claims under Article 17(2)(a) for the following reasons:
1. pri Claims Nos.: 1-15 , 21 because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-15, 21 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.: - because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
See FURTHER INFORMATION SHEET PCT/ISA/210
D Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple Inventions in this international application, as follows:
1. I I As an required additional search fees were timely paid by the applicant, this International Search Report covers all I— I searchable claims.
2. I I As aU searchable claims could be searched without effort Justifying an additional fee, this Authority did not Invite payment of any additional fee.
a I I As only some of the required additional search fees were timely paid by the applicant, this International Search Report < — I c coovveerrss o onnllvy t thhoossee c cllaaiimmss f foorr w whhiicchh f feeeess w weerree n p-aϋidd., s sopβecciiflficcaallllvy c cllaaiimmss N Nooss-.::
4. No required additional search fees were timely paid by the applicant Consequently, this International Search Report Is restricted to the invention first mentioned In the claims; it Is covered by claims Nos.:
Remark on Protest I I The additional search fees were accompanied by the applicant's protest
I I No protest accompanied the payment of additional search fees.
Form PCT/ISA 210 (continuation of first sheet (1)) (July 1998) International Application No. PCTλlS 99 /18237
FURTHER INFORMATION CONTINUED FROM PCT/ISA 210
Continuation of Box 1.2
Present claims 1-28 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT 1s to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds described in Table I and closely related compounds, with due regard to the general idea underlying the present invention.
Claims searched Incompletely: 1-28
The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no International search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case Irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.
Infbnnflbon on pβtβnt family members
" PCT/US 99/18237
Patent document Pi-fcllcatJon Patent family Publication cited In search report date members) date
EP 0947506 A 06-10-1999 JP 11322712 A 24-11-1999
WO 9837882 A 03-09-1998 AU 6181698 A 18-09-1998
ZA 9800825 A 19-10-1998
UO 9820893 A 22-05-1998 US 5780484 A 14-07-1998
AU 5439798 A 03-06-1998
EP 0941113 A 15-09-1999
PL 333286 A 22-11-1999
WO 9526337 A 05-10-1995 US 5744485 A 28-04-1998
AU 704475 B 22-04-1999
AU 2194395 A 17-10-1995
CA 2186380 A 05-10-1995
EP 0754176 A 22-01-1997
JP 9510974 T 04-11-1997
NZ 283599 A 26-06-1998
WO 9615101 A 23-05-1996 US 5543423 A 06-08-1996
AU 689991 B 09-04-1998
AU 4109996 A 06-06-1996
BR 9509698 A 30-06-1998
CA 2224198 A 23-05-1996
CZ 9701491 A 15-10-1997
EP 0797567 A 01-10-1997
FI 972086 A 15-05-1997
HU 77977 A 28-01-1999
JP 10509151 T 08-09-1998
NO 972217 A 17-06-1997
NZ 296474 A 28-01-1999
PL 320227 A 15-09-1997
SK 61197 A 05-11-1996
ZA 9509304 A 29-05-1996
US 5470881 A 28-11-1995 US 5629344 A 13-05-1997
DE 4038692 A 11-06-1992 NONE
EP 0528776 A 24-02-1993 AT 172114 T 15-10-1998
AU 671805 B 12-09-1996
AU 2463192 A 16-03-1993
CA 2114239 A 14-02-1993
DE 69227324 D 19-11-1998
DE 69227324 T 29-04-1999
EP 0661968 A 12-07-1995
ES 2123005 T 01-01-1999
FI 940637 A 11-02-1994
HU 65946 A 29-08-1994 P 6509801 T 02-11-1994
NO 940400 A 07-02-1994
WO 9303718 A 04-03-1993
US 5679713 A 21-10-1997
W0 9522525 A 24-08-1995 US 5610165 A 11-03-1997
AU 1842995 A 04-09-1995
EP 0541497 A 12-05-1993 IT 1249728 B 09-03-1995
Form PCT/ISA 210 (patent tamiy annex) (July 1W2)
Figure imgf000009_0001
Form PCT/.8A/210 (patent famty amex) (J y 1992)
PCT/US1999/018237 1998-08-14 1999-08-12 Small molecule carbamates or ureas for vision and memory disorders WO2000009105A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002336060A CA2336060A1 (en) 1998-08-14 1999-08-12 Small molecule carbamates or ureas for vision and memory disorders
EP99942106A EP1105131A2 (en) 1998-08-14 1999-08-12 Small molecule carbamates or ureas for vision and memory disorders
MXPA01000596A MXPA01000596A (en) 1998-08-14 1999-08-12 Small molecule carbamates or ureas for vision and memory disorders.
JP2000564608A JP2002522481A (en) 1998-08-14 1999-08-12 Small molecular carbamates or urea for visual and memory impairment
AU55554/99A AU5555499A (en) 1998-08-14 1999-08-12 Small molecule carbamates or ureas for vision and memory disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/134,475 US6395758B1 (en) 1998-08-14 1998-08-14 Small molecule carbamates or ureas for vision and memory disorders
US09/134,475 1998-08-14

Publications (2)

Publication Number Publication Date
WO2000009105A2 WO2000009105A2 (en) 2000-02-24
WO2000009105A3 true WO2000009105A3 (en) 2000-06-02

Family

ID=22463564

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/018237 WO2000009105A2 (en) 1998-08-14 1999-08-12 Small molecule carbamates or ureas for vision and memory disorders

Country Status (7)

Country Link
US (1) US6395758B1 (en)
EP (1) EP1105131A2 (en)
JP (1) JP2002522481A (en)
AU (1) AU5555499A (en)
CA (1) CA2336060A1 (en)
MX (1) MXPA01000596A (en)
WO (1) WO2000009105A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008960B1 (en) 1999-03-02 2006-03-07 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US20030199574A1 (en) * 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
US7977385B2 (en) * 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
EP1480678B1 (en) * 2002-02-13 2009-04-15 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
US20050137124A1 (en) * 2002-08-09 2005-06-23 Vitreo-Retinal Technologies, Inc. A California Corporation Agents for intravitreal administration to treat or prevent disorders of the eye

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370378A2 (en) * 1988-11-19 1990-05-30 Hoechst Aktiengesellschaft Pyrrolidine-2-carboxylic-acid derivatives with a psychotropic activity
DE4038692A1 (en) * 1990-12-05 1992-06-11 Heverhagen Ulrich Agent for treating eye disorders esp. grey star - consists of demineralised sterilised water contg. urea and/or other substances, such as glycol, animal protein, plant extracts etc.
EP0528776A1 (en) * 1991-08-13 1993-02-24 Aktiebolaget Astra Pharmaceutical composition containing carbachol and other cholinergic substances
EP0541497A1 (en) * 1991-11-06 1993-05-12 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Prolineamide derivatives as enhancers of learning processes and memory and pharmaceutical compositions containing same
WO1995022525A1 (en) * 1994-02-17 1995-08-24 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
WO1995026337A1 (en) * 1994-03-25 1995-10-05 Vertex Pharmaceuticals Incorporated Novel carbamates and ureas as modifiers of multi-drug resistance
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
WO1996015101A1 (en) * 1994-11-16 1996-05-23 Vertex Pharmaceuticals Incorporated Novel amino acid derivatives with improved multi-drug resistance activity
WO1998020893A1 (en) * 1996-11-13 1998-05-22 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors
WO1998037882A1 (en) * 1997-02-27 1998-09-03 Guilford Pharmaceuticals Inc. Method of using neurotrophic carbamates and ureas
EP0947506A1 (en) * 1998-03-24 1999-10-06 Pfizer Products Inc. 2-Aza-bicyclo[2.2.1]heptane derivatives and their use as rotamase inhibitors

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070361A (en) 1977-04-21 1978-01-24 E. R. Squibb & Sons, Inc. Mercaptoalkylsulfonyl proline and pipecolic acid and esters thereof
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4578474A (en) 1980-06-23 1986-03-25 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4310461A (en) 1980-06-23 1982-01-12 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4390695A (en) 1980-06-23 1983-06-28 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
GR75019B (en) 1980-09-17 1984-07-12 Univ Miami
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
DE3174844D1 (en) 1980-10-23 1986-07-24 Schering Corp Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
ZA826022B (en) 1981-08-21 1983-08-31 Univ Miami Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides
DE3360065D1 (en) 1982-03-08 1985-03-28 Schering Corp Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
US4531964A (en) 1982-09-13 1985-07-30 Nippon Kayaku Kabushiki Kaisha Heterocyclic compound and a herbicidal composition containing said compound
US4574079A (en) 1983-05-27 1986-03-04 Gavras Haralambos P Radiolabeled angiotensin converting enzyme inhibitors for radiolabeling mammalian organ sites
US4593102A (en) 1984-04-10 1986-06-03 A. H. Robins Company, Inc. N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position
DE3508251A1 (en) 1985-03-08 1986-09-11 Merck Patent Gmbh, 6100 Darmstadt Dipeptides
CN86101850A (en) 1985-03-22 1987-02-04 森得克斯(美国)有限公司 N, the manufacture method and the purposes of N '-dialkyl group guanidine radicals dipeptides
DE3774975D1 (en) 1986-09-10 1992-01-16 Syntex Inc SELECTIVE AMIDINATION OF DIAMINES.
US4782071A (en) * 1986-11-03 1988-11-01 Warner-Lambert Company Tetrasubstituted urea cholinergic agents
IT1206078B (en) 1987-06-03 1989-04-14 Polifarma Spa PROCEDURE FOR THE PRODUCTION OF 3-INDOLPIRUVIC ACID AND ITS DERIVATIVES THEIR PHARMACEUTICAL USE
US5187156A (en) 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
IL90872A0 (en) 1988-07-08 1990-02-09 Smithkline Beckman Corp Retroviral protease binding peptides
EP0378318A1 (en) 1989-01-11 1990-07-18 Merck & Co. Inc. Process for synthesis of FK-506 and tricarbonyl intermediates
US5162500A (en) 1989-04-15 1992-11-10 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Poststatin and related compounds or salts thereof
US5359138A (en) 1989-04-15 1994-10-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Poststatin and related compounds or salts thereof
US5164525A (en) 1989-06-30 1992-11-17 Merck & Co., Inc. Synthetic process for fk-506 type macrolide intermediates
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
NZ234883A (en) 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5115098A (en) 1990-02-28 1992-05-19 President And Fellows Of Harvard College End-blocked peptides inhibiting binding capacity of gp120
JPH04211648A (en) 1990-07-27 1992-08-03 Nippon Kayaku Co Ltd Keto-acid amide derivative
US5192773A (en) 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
AU8740991A (en) 1990-08-24 1992-03-17 Upjohn Company, The Peptides containing amino-polyols as transition-state mimics
WO1992004370A1 (en) 1990-08-29 1992-03-19 Vertex Pharmaceuticals Incorporated Modified di- and tripeptidyl immunosuppressive compounds
GB2247456A (en) 1990-09-03 1992-03-04 Fujisawa Pharmaceutical Co Tetrahydropyrane compounds, a process for their production and a pharmaceutical composition containing the same
AU1677092A (en) 1991-03-20 1992-10-21 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
IT1245712B (en) 1991-04-09 1994-10-14 Boehringer Mannheim Italia USEFUL HETEROCYCLIC AMINES THERAPY OF ASTHMA AND AIRWAY INFLAMMATION
US5147877A (en) 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
EP0584217A1 (en) 1991-05-08 1994-03-02 Vertex Pharmaceuticals Incorporated Rfkbp: a novel prolyl isomerase and rapamycin/fk506 binding protein
DE69229782T2 (en) 1991-05-09 2000-04-27 Vertex Pharma NEW IMMUNE SUPPRESSIVE CONNECTIONS
MX9202466A (en) 1991-05-24 1994-06-30 Vertex Pharma NOVELTY IMMUNOSUPPRESSIVE COMPOUNDS.
JPH05178824A (en) 1991-08-05 1993-07-20 Takeda Chem Ind Ltd Asparagine derivative and its use
WO1993007269A1 (en) 1991-10-11 1993-04-15 Vertex Pharmaceuticals Incorporated ISOLATION OF AN Mr 52,000 FK506 BINDING PROTEIN AND MOLECULAR CLONING OF A CORRESPONDING HUMAN cDNA
MX9205821A (en) 1991-10-11 1993-04-01 Ciba Geigy Ag PIRIMIDINIL- AND TRIAZINILETERES AND -TIOETERES AND PROCEDURE FOR THE PREPARATION.
AU3278293A (en) 1991-12-20 1993-07-28 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
US5594002A (en) * 1992-02-28 1997-01-14 Pfizer Inc Benzazabicyclic carbamates as novel cholinesterase inhibitors
AU4388893A (en) 1992-05-20 1993-12-13 Vertex Pharmaceuticals Incorporated Method of detecting tissue-specific FK506 binding protein messenger RNAs and uses thereof
IT1254373B (en) 1992-05-29 1995-09-14 HETEROPROSTANOIDS, PROCEDURE FOR THEIR PREPARATION AND THEIR EMPLOYE THERAPEUTIC.
US5334719A (en) 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (en) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
NZ314207A (en) 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
AU5748194A (en) 1992-12-11 1994-07-04 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
DE4302860A1 (en) 1993-01-22 1994-08-04 Chemie Linz Deutschland N-Cyclic and N, N'dicyclic ureas
US5252579A (en) 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
US5631017A (en) 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5319098A (en) 1993-05-18 1994-06-07 Celgene Corporation Process for the stereoselective preparation of L-alanyl-L-proline
IT1270882B (en) 1993-10-05 1997-05-13 Isagro Srl FUNGICIDE-BASED OLIGOPEPTIDES
EP0677039B1 (en) 1993-11-04 1999-03-10 Abbott Laboratories Cyclobutane derivatives as inhibitors of squalene synthetase and protein farnesyltransferase
MX9603909A (en) 1994-03-07 1997-03-29 Vertex Pharma Sulphonamide derivatives as aspartyl protease inhibitors.
US6057119A (en) 1994-06-17 2000-05-02 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5488816A (en) 1994-07-21 1996-02-06 Boehringer Mannheim Corporation Method and apparatus for manufacturing a coagulation assay device in a continuous manner
JP4470226B2 (en) 1994-08-18 2010-06-02 アリアド・ファーマシューティカルズ・インコーポレイテッド New multimerizing agent
US5543423A (en) 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
US5621108A (en) 1994-12-05 1997-04-15 Trustees Of The University Of Pennsylvania Processes and intermediates for preparing macrocycles
US5691372A (en) 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5726184A (en) 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity
US5614547A (en) 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5811434A (en) 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
WO1998024805A1 (en) 1996-12-06 1998-06-11 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
NZ336386A (en) * 1996-12-31 2001-09-28 Guilford Pharm Inc An urea or carbamate derivative of heterocyclic thioester useful for effecting neuronal activity
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370378A2 (en) * 1988-11-19 1990-05-30 Hoechst Aktiengesellschaft Pyrrolidine-2-carboxylic-acid derivatives with a psychotropic activity
DE4038692A1 (en) * 1990-12-05 1992-06-11 Heverhagen Ulrich Agent for treating eye disorders esp. grey star - consists of demineralised sterilised water contg. urea and/or other substances, such as glycol, animal protein, plant extracts etc.
EP0528776A1 (en) * 1991-08-13 1993-02-24 Aktiebolaget Astra Pharmaceutical composition containing carbachol and other cholinergic substances
EP0541497A1 (en) * 1991-11-06 1993-05-12 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Prolineamide derivatives as enhancers of learning processes and memory and pharmaceutical compositions containing same
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
WO1995022525A1 (en) * 1994-02-17 1995-08-24 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
WO1995026337A1 (en) * 1994-03-25 1995-10-05 Vertex Pharmaceuticals Incorporated Novel carbamates and ureas as modifiers of multi-drug resistance
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
WO1996015101A1 (en) * 1994-11-16 1996-05-23 Vertex Pharmaceuticals Incorporated Novel amino acid derivatives with improved multi-drug resistance activity
WO1998020893A1 (en) * 1996-11-13 1998-05-22 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors
WO1998037882A1 (en) * 1997-02-27 1998-09-03 Guilford Pharmaceuticals Inc. Method of using neurotrophic carbamates and ureas
EP0947506A1 (en) * 1998-03-24 1999-10-06 Pfizer Products Inc. 2-Aza-bicyclo[2.2.1]heptane derivatives and their use as rotamase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BALASPIRI, LAJOS ET AL: "Producing new tripeptide derivatives of anti-amnesic activity", XP002130597, retrieved from STN Database accession no. 110:24315 HCA *
PESSAH, I. N. (1): "Role for the major T-cell immunophilin FKBP12 in mediating neurotoxicity of non-coplanar PCBs.", NEUROTOXICOLOGY AND TERATOLOGY, (MAY-JUNE, 1998) VOL. 20, NO. 3, PP. 350. MEETING INFO.: TWENTY-SECOND ANNUAL MEETING OF THE NEUROBEHAVIORAL TERATOLOGY SOCIETY SAN DIEGO, CALIFORNIA, USA JUNE 20-24, 1998 NEUROBEHAVIORAL TERATOLOGY SOCIETY., XP000878599 *

Also Published As

Publication number Publication date
EP1105131A2 (en) 2001-06-13
WO2000009105A2 (en) 2000-02-24
MXPA01000596A (en) 2002-04-08
CA2336060A1 (en) 2000-02-24
JP2002522481A (en) 2002-07-23
AU5555499A (en) 2000-03-06
US6395758B1 (en) 2002-05-28

Similar Documents

Publication Publication Date Title
Parsons et al. Heterologous desensitization of the inhibitory A1 adenosine receptor-adenylate cyclase system in rat adipocytes. Regulation of both Ns and Ni.
Behan et al. Oxidative stress as a mechanism for quinolinic acid‐induced hippocampal damage: protection by melatonin and deprenyl
Stone et al. Brain adrenergic receptors and resistance to stress
Brawley et al. β1‐, β2‐and atypical β‐adrenoceptor‐mediated relaxation in rat isolated aorta
HERMAN et al. Regulation of basal corticotropin-releasing hormone and arginine vasopressin messenger ribonucleic acid expression in the paraventricular nucleus: effects of selective hypothalamic deafferentations
Germack et al. β‐adrenoceptor subtype expression and function in rat white adipocytes
Kneteman et al. THE METABOLIC IMPACT OF RAPAMYCIN (SIROLIMUS) IN CHRONIC CANINE ISLET GRAFT RECIPIENTS1
WO2000009105A3 (en) Small molecule carbamates or ureas for vision and memory disorders
JONES et al. A re‐appraisal of the post‐testicular action and toxicity of chlorinated antifertility compounds
Clarkson et al. Effects of bazedoxifene alone and with conjugated equine estrogens on coronary and peripheral artery atherosclerosis in postmenopausal monkeys
Kosten et al. Six-month follow-up of short-term pharmacotherapy for cocaine dependence
Georgala et al. Pretibial myxedema as the initial manifestation of Graves’ disease
Tavani et al. Risk factors for epithelial ovarian cancer in women under age 45
Hayashida et al. Neurogenic nitric oxide mediates relaxation of canine corpus cavernosum
Marcoli et al. Trazodone is a potent agonist at 5-HT2C receptors mediating inhibition of the N-methyl-D-aspartate/nitric oxide/cyclic GMP pathway in rat cerebellum
GOMES et al. Improved contractility of obstructed bladders after Tadenan treatment is associated with reversal of altered myosin isoform expression
AU7213196A (en) Method of treating the navicular disease in horses
US20010018434A1 (en) Preparation and method for the treatment and prevention of dementia disorders
Chu et al. Mechanisms and sites of ocular action of 7-hydroxy-2-dipropylaminotetralin: a dopamine3 receptor agonist
Crone et al. Neuronal nitric oxide synthase in the canine prostate: aging, sex steroid, and pathology correlations
Hokonohara et al. The effects of oxiracetam (CT-848) on local cerebral glucose utilization after focal cerebral ischemia in rats
Teixeira et al. Atypical β-adrenoceptor subtypes mediate relaxations of rabbit corpus cavernosum
Gomez et al. Manipulation of androgens causes different energetic responses to cold in 60-and 40-day-old male rats
Malone et al. Serotonin and major depression
Siwers et al. A quantitative approach to the initial clinical trial of tricyclic antidepressants: a comparison of Leo 640 and nortriptyline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2336060

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999942106

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 55554/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000596

Country of ref document: MX

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999942106

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999942106

Country of ref document: EP